Amgen Inc
$ 298.81
1.01%
17 Oct - close price
- Market Cap 160,867,910,000 USD
- Current Price $ 298.81
- High / Low $ 299.37 / 293.14
- Stock P/E 24.45
- Book Value 13.80
- EPS 12.22
- Next Earning Report 2025-10-29
- Dividend Per Share $9.26
- Dividend Yield 3.13 %
- Next Dividend Date -
- ROA 0.08 %
- ROE 0.99 %
- 52 Week High 330.26
- 52 Week Low 247.06
About
Amgen Inc. is a prominent multinational biopharmaceutical company headquartered in Thousand Oaks, California, renowned for its innovative therapies rooted in recombinant DNA technology. Specializing in oncology, nephrology, and inflammation, Amgen leverages its expertise in molecular biology to develop and commercialize biologic products that enhance patient outcomes. With a robust drug pipeline and a strong competitive position in the biotechnology sector, Amgen remains at the forefront of medical advancements, actively addressing global unmet medical needs and maintaining a commitment to improving the quality of life for patients worldwide.
Analyst Target Price
$311.65
Quarterly Earnings
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-08-05 | 2025-05-01 | 2025-02-04 | 2024-10-30 | 2024-08-06 | 2024-05-02 | 2024-02-06 | 2023-10-31 | 2023-08-03 | 2023-04-27 | 2023-01-31 | 2022-11-03 |
| Reported EPS | 6.02 | 4.9 | 5.31 | 5.58 | 4.97 | 3.96 | 4.71 | 4.96 | 5 | 3.98 | 4.09 | 4.7 |
| Estimated EPS | 5.28 | 4.26 | 5.08 | 5.11 | 5.01 | 3.87 | 4.61 | 4.67 | 4.49 | 3.85 | 4.1 | 4.44 |
| Surprise | 0.74 | 0.64 | 0.23 | 0.47 | -0.04 | 0.09 | 0.1 | 0.29 | 0.51 | 0.13 | -0.01 | 0.26 |
| Surprise Percentage | 14.0152% | 15.0235% | 4.5276% | 9.1977% | -0.7984% | 2.3256% | 2.1692% | 6.2099% | 11.3586% | 3.3766% | -0.2439% | 5.8559% |
Next Quarterly Earnings
| Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|
| Reported Date | 2025-10-29 | 2026-02-02 | 2026-04-29 |
| Fiscal Date Ending | 2025-09-30 | 2025-12-31 | 2026-03-31 |
| Estimated EPS | 5.02 | ||
| Currency | USD | USD | USD |
Previous Dividend Records
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2025-09-12 | 2025-06-06 | 2025-03-07 | 2024-12-09 | 2024-09-06 | 2024-06-07 | 2024-03-07 | 2023-12-08 | 2023-09-08 | 2023-06-08 |
| Amount | $2.38 | $2.38 | $2.38 | $2.25 | $2.25 | $2.25 | $2.25 | $2.13 | $2.13 | $2.13 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AMGN
2025-10-17 16:00:46
In the current market session, Amgen Inc. ( NASDAQ:AMGN ) share price is at $295.58, after a 0.08% drop. Over the past month, the stock increased by 3.56%, but over the past year, it actually fell by 6.68%.
2025-10-17 14:19:58
President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades.
2025-10-17 10:22:00
Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 results.
2025-10-16 17:40:28
William Blair initiated coverage for Climb Bio ( NASDAQ:CLYM ) , citing the potential of the company's budoprutug, under development for autoimmune indications, including: Phase 1b/2a immune thrombocytopenia ( ITP ) trial FPI achieved, enrollment ongoing.
2025-10-16 13:31:00
Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market reach.
2025-10-15 21:50:04
In the closing of the recent trading day, Amgen (AMGN) stood at $297.32, denoting a +1.18% move from the preceding trading day.
